Cargando…

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy

BACKGROUND: Fabry disease (FD) is a treatable X-linked condition leading to progressive cardiac disease, arrhythmia and premature death. We aimed to increase awareness of the arrhythmogenicity of Fabry cardiomyopathy, by comparing device usage in patients with Fabry cardiomyopathy and sarcomeric HCM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vijapurapu, Ravi, Bradlow, William, Leyva, Francisco, Moon, James C., Zegard, Abbasin, Lewis, Nigel, Kotecha, D., Jovanovic, Ana, Hughes, Derralynn A., Woolfson, Peter, Steeds, Richard P., Geberhiwot, Tarekegn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734227/ https://www.ncbi.nlm.nih.gov/pubmed/34991670 http://dx.doi.org/10.1186/s13023-021-02133-4

Ejemplares similares

Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease
por: Vijapurapu, Ravi, et al.
Publicado: (2023)

A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
por: Nordin, Sabrina, et al.
Publicado: (2019)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Atherosclerosis in Fabry Disease—A Contemporary Review
por: Roy, Ashwin, et al.
Publicado: (2021)

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
por: Augusto, João B, et al.
Publicado: (2020)

Cardiac Phenotype of Prehypertrophic Fabry Disease
por: Nordin, Sabrina, et al.
Publicado: (2018)

Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis
por: Baig, Shanat, et al.
Publicado: (2020)

Fabry Disease Presenting with Hypertrophic Cardiomyopathy and Tricuspid Regurgitation
por: Cho, Sang-Cheol, et al.
Publicado: (2016)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Increased cardiac involvement in Fabry disease using blood-corrected native T1 mapping
por: Nickander, Jannike, et al.
Publicado: (2023)

Surgical management of left ventricular outflow obstruction in hypertrophic cardiomyopathy
por: Howell, Neil, et al.
Publicado: (2015)

Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy
por: Meucci, Maria Chiara, et al.
Publicado: (2022)

Fabry Disease: More than a Phenocopy of Hypertrophic Cardiomyopathy
por: Stankowski, Kamil, et al.
Publicado: (2023)

Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography
por: Turvey, Lauren, et al.
Publicado: (2021)

Left Ventricular Assist Device Support for Fabry Cardiomyopathy: A Case Series
por: Omid Kiamanesh, M.D., et al.
Publicado: (2020)

Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic
por: Zemánek, David, et al.
Publicado: (2022)

Hypertrophic obstructive cardiomyopathy caused by Fabry disease: implications for surgical myectomy
por: Frustaci, Andrea, et al.
Publicado: (2023)

Cardiac operations and interventions during the COVID-19 pandemic: a nationwide perspective
por: Leyva, Francisco, et al.
Publicado: (2021)

Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy
por: Leyva, Francisco, et al.
Publicado: (2018)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018)

Greyzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction >35%
por: Zegard, Abbasin, et al.
Publicado: (2021)

Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
por: Müntze, Jonas, et al.
Publicado: (2018)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

Native T1 mapping versus CMR Feature Tracking (FT) derived strain analysis for the assessment of cardiac disease manifestation in Anderson Fabry
por: Reid, Anna B, et al.
Publicado: (2016)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Cardiac Resynchronization Therapy Using Quadripolar Versus Non‐Quadripolar Left Ventricular Leads Programmed to Biventricular Pacing With Single‐Site Left Ventricular Pacing: Impact on Survival and Heart Failure Hospitalization
por: Leyva, Francisco, et al.
Publicado: (2017)

Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction
por: Yagi, Nobuichiro, et al.
Publicado: (2021)

GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
por: Chaves-Markman, Ândrea Virgínia, et al.
Publicado: (2019)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias
por: Okafor, Osita, et al.
Publicado: (2019)

Sex‐Specific Differences in Survival and Heart Failure Hospitalization After Cardiac Resynchronization Therapy With or Without Defibrillation
por: Leyva, Francisco, et al.
Publicado: (2019)

Inflammatory Fabry Cardiomyopathy Demonstrated Using Simultaneous [(18)F]-FDG PET-CMR
por: Orsborne, Christopher, et al.
Publicado: (2023)

Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease
por: Limongelli, Giuseppe, et al.
Publicado: (2018)

Description of a New GLA Gene Variant in a Patient with Hypertrophic Cardiomyopathy. Is it Fabry Disease?
por: Bittencourt, Marcelo Imbroinise
Publicado: (2019)

Left Ventricular Assist Device With a Left Atrial Inflow Cannula for Hypertrophic Cardiomyopathy
por: Kiamanesh, Omid, et al.
Publicado: (2020)

Diagnostic yield of a heart failure referral pathway using N-terminal pro-brain natriuretic peptide
por: Zegard, Abbasin, et al.
Publicado: (2023)

Long‐term outcomes of cardiac resynchronization therapy in adult congenital heart disease
por: Leyva, Francisco, et al.
Publicado: (2019)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dns9u815dmg9l78otluiqnjlgm